newsfilter
← Earnings
Earnings Releases·

Ligand Pharmaceuticals — Third Quarter 2026 Earnings Summary

Ligand Pharmaceuticals reported third-quarter 2026 royalty revenue of $70.3 million, a 51% increase year-over-year, driven by the newly acquired XOMA portfolio and continued sales of key assets like Filspari. The company raised its full-year 2026 adjusted diluted earnings per share guidance to a range of $9.50 to $9.75, while reaffirming its revenue projections for the year. Ligand's portfolio has expanded to over 200 assets following the acquisition of XOMA Royalty and additional strategic investments in Santen's Ryjunea and AvenCell Therapeutics.

Company
LIGAND PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology